Characteristics of cognitive impairment in adult asymptomatic moyamoya disease

Shihao He(Chinese Academy of Medical Sciences & Peking Union Medical College), Rong Wang(Yinchuan First People's Hospital), Xun Ye(Capital Medical University), Junshi Shao(Capital Medical University), Ziqi Liu(Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital), Li Yan Yuan(Beijing Normal-Hong Kong Baptist University), Ran Duan(Central South University), Li Tian(Beijing Normal University), Shusen Qin(Capital Medical University), Cunxin Tan(Peking University)
BMC Neurology
August 31, 2020
10.1186/s12883-020-01898-8
Cited by 39

Related Papers

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
|New England Journal of Medicine|2015|241
Artificial intelligence in educational assessment: ‘Breakthrough? Or buncombe and ballyhoo?’
|Journal of Computer Assisted Learning|2021|191
Association between white matter impairment and cognitive dysfunction in patients with ischemic Moyamoya disease
|BMC Neurology|2020|30
Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
|Cancer Research|2020|30
Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease
|Stroke|2023|30